SCHEMBL1760828

SCHEMBL1760828

COc1ccc(CN2C(=O)SCC2C(=O)O)cc1

nearest known ligand 0.54

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
MMP9 P14780 2/20 0.54
MMP2 P08253 1/20 0.54
MEN1 O00255 1/20 0.51
KMT2A Q03164 1/20 0.51
ALDH1A1 P00352 1/20 0.45
SIGMAR1 Q99720 2/20 0.44
POLB P06746 2/20 0.44
GAA P10253 2/20 0.44
RAB9A P51151 1/20 0.44
CMA1 P23946 1/20 0.44
GSK3A P49840 2/20 0.44
GSK3B P49841 2/20 0.44
HRH3 Q9Y5N1 1/20 0.43
SMN1; SMN2 Q16637 1/20 0.43
FFAR2 O15552 1/20 0.42
MMP1 P03956 1/20 0.42
MMP3 P08254 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1760840 1.00 MMP9 (0.54) MMP9MMP2MEN1KMT2AALDH1A1
SCHEMBL1760825 0.90 MMP2 (0.51) MMP9MMP2MEN1KMT2AALDH1A1
SCHEMBL1760829 0.90 MMP2 (0.51) MMP9MMP2MEN1KMT2AALDH1A1
SCHEMBL3086045 0.84 MMP2 (0.63) MMP9MMP2MEN1KMT2AALDH1A1
SCHEMBL1760823 0.84 MMP2 (0.46) MMP9MMP2MEN1KMT2AALDH1A1
SCHEMBL1760822 0.84 MMP2 (0.46) MMP9MMP2MEN1KMT2AALDH1A1
SCHEMBL1760815 0.83 MMP2 (0.54) MMP9MMP2MEN1KMT2AALDH1A1
SCHEMBL1760826 0.83 MMP2 (0.54) MMP9MMP2MEN1KMT2AALDH1A1
SCHEMBL1760882 0.82 MMP2 (0.45) MMP9MMP2MEN1KMT2AALDH1A1
SCHEMBL14037540 0.82 MMP2 (0.45) MMP9MMP2MEN1KMT2AALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8039465-B2 Cytoskeletal active compounds, composition and use INSPIRE PHARMACEUTICALS, INC. (US) 2011-10-18 US disclosed
US-7947850-B2 Process for the preparation of 3,4-disubstituted-thiazolidin-2-ones INSPIRE PHARMACEUTICALS, INC. (US) 2011-05-24 US disclosed
US-20100130572-A1 CYTOSKELETAL ACTIVE COMPOUNDS, COMPOSITION AND USE LAMPE JOHN W 2010-05-27 US disclosed
US-7666861-B2 Cytoskeletal active compounds, composition and use INSPIRE PHARMACEUTICALS, INC. (US) 2010-02-23 US disclosed
EP-1996192-A2 PROCESS FOR THE PREPARATION OF 3,4-DISUBSTITUTED-THIAZOLIDIN-2-ONES Inspire Pharmaceuticals, Inc. (US) 2008-12-03 EP disclosed
US-20080287683-A1 PROCESS FOR THE PREPARATION OF 3,4-DISUBSTITUTED-THIAZOLIDIN-2-ONES DECAMP JONATHAN B 2008-11-20 US disclosed
US-7414137-B2 Process for the preparation of 3,4-disubstituted-thiazolidin-2-ones INSPIRE PHARMACEUTICALS, INC. (US) 2008-08-19 US disclosed
CN-101160315-A Cytoskeletal active compounds, composition and use INSPIRE PHARMACEUTICALS INC (US) 2008-04-09 CN disclosed
US-20080076735-A1 CYTOSKELETAL ACTIVE COMPOUNDS, COMPOSITION AND USE CHATTEM INC. 2008-03-27 US disclosed
US-7320974-B2 Cytoskeletal active compounds, compositions and use INSPIRE PHARMACEUTICALS, INC. (US) 2008-01-22 US disclosed
EP-1866316-A2 CYTOSKELETAL ACTIVE COMPOUNDS, COMPOSITION AND USE Inspire Pharmaceuticals, Inc. (US) 2007-12-19 EP disclosed
US-20070225504-A1 PROCESS FOR THE PREPARATION OF 3,4-DISUBSTITUTED-THIAZOLIDIN-2-ONES INSPIRE PHARMACEUTICALS, INC. 2007-09-27 US disclosed
WO-2007109786-A2 PROCESS FOR THE PREPARATION OF 3,4-DISUBSTITUTED-THIAZOLIDIN-2-ONES INSPIRE PHARMACEUTICALS, INC. (US) 2007-09-27 WO disclosed
WO-2006104897-A2 CYTOSKELETAL ACTIVE COMPOUNDS, COMPOSITION AND USE INSPIRE PHARMACEUTICALS, INC. (US) 2006-10-05 WO disclosed
US-20060217427-A1 Cytoskeletal active compounds, compositions and use INSPIRE PHARMACEUTICALS, INC. 2006-09-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070225504-A1 PROCESS FOR THE PREPARATION OF 3,4-DISUBSTITUTED-THIAZOLIDIN-2-ONES ACTR2, ACTR5, ACTR3 MMP9 4859/4885MMP2 4269/4885MEN1 1636/4885
US-20060217427-A1 Cytoskeletal active compounds, compositions and use RHOA, ACTB, ROCK1 MMP9 3742/4885MMP2 2595/4885MEN1 3613/4885
US-20080287683-A1 PROCESS FOR THE PREPARATION OF 3,4-DISUBSTITUTED-THIAZOLIDIN-2-ONES ACTR2, ACTR5, ACTR3 MMP9 4859/4885MMP2 4269/4885MEN1 1636/4885
US-20100130572-A1 CYTOSKELETAL ACTIVE COMPOUNDS, COMPOSITION AND USE RHOA, ACTB, ROCK1 MMP9 3700/4885MMP2 2655/4885MEN1 3748/4885
US-20080076735-A1 CYTOSKELETAL ACTIVE COMPOUNDS, COMPOSITION AND USE RHOA, ACTB, ROCK1 MMP9 3700/4885MMP2 2655/4885MEN1 3748/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.